Understanding RSV ‍and Why It’s a Threat to ⁤Seniors

Respiratory Syncytial virus (RSV) is⁤ a common respiratory virus that usually causes mild, cold-like symptoms. Though, for older adults, ⁣RSV⁤ can ⁣lead to severe illness, including pneumonia and hospitalization. Prior to the advancement of vaccines, RSV was estimated to cause approximately 60,000-160,000 ‍hospitalizations and 6,000-10,000 deaths annually among adults 65⁤ years and older in ⁣the United States.

The virus⁤ spreads through close contact with ‍infected individuals, often via respiratory⁣ droplets produced during coughing or sneezing. Older‍ adults ‍are particularly vulnerable due to age-related⁢ decline in immune function and the presence of underlying health conditions like heart disease or chronic lung disease.

The Arexvy Vaccine: How It Works

Arexvy,developed by ⁢GSK,is a recombinant subunit vaccine. This means it doesn’t use a live virus. Instead,it contains a stabilized prefusion F protein,a key⁤ component of the RSV⁣ virus that triggers an immune response. The vaccine works⁤ by prompting the body to ‍create antibodies that recognize and neutralize the virus, preventing infection or ‍reducing the severity of illness.

Clinical trials demonstrated a vaccine efficacy of ⁢82.6% against ⁣RSV-associated lower respiratory tract disease (LRTD) ⁢in adults 60 ‍years and older. Efficacy was observed across various subgroups, including those with underlying medical conditions.

FDA Approval and Recommendations⁣ (September 18,2025)

The Food and Drug Management (FDA) initially approved Arexvy on ⁣May 3,2023. However, recommendations regarding its⁤ use have evolved. As of September 18,‍ 2025, the Centers for Disease⁢ control and Prevention (CDC) Advisory committee on Immunization Practices (ACIP) ‍recommends that adults aged‍ 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider.

This shared decision-making approach acknowledges⁣ that not all older⁤ adults will benefit equally from vaccination. Factors considered include individual health status,‍ risk of RSV exposure, and personal preferences. The⁤ ACIP’s recommendations are not legally binding but are⁢ highly influential in guiding vaccination practices.

Safety and Side Effects

In clinical trials, arexvy was generally ‍well-tolerated. The most common side effects reported were ⁤pain at the injection site, ⁢fatigue, muscle aches, headache, and joint pain. Serious adverse events were rare.

However,a⁢ potential safety signal emerged following the initial rollout of the vaccine. An increased risk of Guillain-Barré ‍syndrome (GBS), a rare neurological disorder, was observed in some recipients. The FDA and CDC ⁢continue to monitor this ⁤potential risk and provide updated guidance as needed. Individuals who develop symptoms suggestive of GBS after vaccination should seek immediate medical attention.

Who Should Get the RSV Vaccine?